Last reviewed · How we verify

Retention of urine — Treatment Landscape & Competitive Intelligence

Retention of urine (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Retention of urine, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Bloxiverz NEOSTIGMINE Fresenius Kabi Cholinesterase Inhibitor Acetylcholinesterase 2013-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Retention of urine
  2. Fresenius Kabi · 1 drug in Retention of urine

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Retention of urine:

Cite this brief

Drug Landscape (2026). Retention of urine — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/retention-of-urine. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing